GILEAD SCIENCES, INC. Cost of Goods Sold, Amortization (Deprecated 2018-01-31)
GILEAD SCIENCES, INC. (GILD) reported Cost of Goods Sold, Amortization (Deprecated 2018-01-31) of $29.30 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-23.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSoldAmortization · last filed 2012-02-23
- GILEAD SCIENCES, INC. cost of goods sold, amortization (deprecated 2018-01-31) for fiscal 2011 was $29.30M, a 14.90% increase from fiscal 2010.
- GILEAD SCIENCES, INC. cost of goods sold, amortization (deprecated 2018-01-31) for fiscal 2010 was $25.50M, a 14.72% decline from fiscal 2009.
- GILEAD SCIENCES, INC. cost of goods sold, amortization (deprecated 2018-01-31) for fiscal 2009 was $29.90M, a 5.97% decline from fiscal 2008.
- GILEAD SCIENCES, INC. cost of goods sold, amortization (deprecated 2018-01-31) for fiscal 2008 was $31.80M.
| Period end | Cost of Goods Sold, Amortization (Deprecated 2018-01-31) 12 month |
|---|---|
| 2011-12-31 | $29.30M 10-K · filed 2012-02-23 |
| 2010-12-31 | $25.50M 10-K · filed 2012-02-23 |
| 2009-12-31 | $29.90M 10-K · filed 2012-02-23 |
| 2008-12-31 | $31.80M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |